Wordt geladen...
Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I–III Clinical Trials
BACKGROUND AND OBJECTIVE: Risankizumab is an anti-interleukin (IL)-23 monoclonal antibody being developed for treatment of moderate to severe plaque psoriasis. This study provided a comprehensive analysis of risankizumab pharmacokinetics in healthy subjects and patients with plaque psoriasis using d...
Bewaard in:
| Gepubliceerd in: | Clin Pharmacokinet |
|---|---|
| Hoofdauteurs: | , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Springer International Publishing
2019
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6769095/ https://ncbi.nlm.nih.gov/pubmed/31054118 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-019-00759-z |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|